GSK results announcement for Q4 and full year 2011
Issued: Tuesday 07 February 2012, London UK
GSK delivers continued underlying sales growth*, R&D progress and improving financial returns to shareholders
- 2011 underlying sales +4% (reported -3%)
- EPS before major restructuring* 114.1p
- Total dividends of 75p
Go to the Quarterly results page
GlaxoSmithKline Enquiries: |
|||
UK Media enquiries: |
David Mawdsley |
+44 (0) 20 8047 5502 |
(London) |
|
Stephen Rea |
+44 (0) 20 8047 5502 |
(London) |
|
Sarah Spencer |
+44 (0) 20 8047 5502 |
(London) |
|
David Daley |
+44 (0) 20 8047 5502 |
(London) |
|
|
|
|
US Media enquiries: |
Kevin Colgan |
+1 919 483 2839 |
(North Carolina) |
|
Mary Anne Rhyne |
+1 919 483 2839 |
(North Carolina) |
|
Sarah Alspach |
+1 919 483 2839 |
(Washington, DC) |
|
Jennifer Armstrong |
+1 919 483 2839 |
(Philadelphia) |
|
|
|
|
Analyst/Investor enquiries: |
Sally Ferguson |
+44 (0) 20 8047 5543 |
(London) |
|
Tom Curry |
+ 1 215 751 5419 |
(Philadelphia) |
|
Gary Davies |
+ 44 (0) 20 8047 5503 |
(London) |
|
Ziba Shamsi |
+ 44 (0) 20 8047 3289 |
(London) |
|
Jeff McLaughlin |
+ 1 215 751 7002 |
(Philadelphia) |
